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ATTRACT = Anti-Tumor necrosis factor Trial in Rheumatoid Arthritis with Concomitant Therapy; CRP = C-reactive protein; IL = interleukin; MTX =
methotrexate; RA = rheumatoid arthritis; TNFα = tumor necrosis factor alpha; VEGF = vascular endothelial growth factor.
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Introduction
Tumor necrosis factor alpha (TNFα) is the name given to a
serum factor that was derived in 1975 from endotoxin-
treated mice and found to be capable of inducing necrosis
of a methylcholanthrene-induced murine sarcoma [1]. The
molecular characterization of TNFα in the 1980s revealed
that it is identical to cachectin, a previously described
serum factor that was found to be responsible for weight
loss and fever in experimental animal models [2,3]. The
diverse biologic activities of TNFα soon became apparent.
Aside from its tumoricidal property, it was recognized that,
following injection into animals or humans, TNFα causes
signs and symptoms of shock, including multi-organ
damage via pro-inflammatory effects on vascular endothe-
lium. The realization that TNFα may play a role in rheuma-
toid arthritis (RA) followed  four demonstrations:  firstly,
its ability to degrade cartilage and bone in vitro; secondly,
its arthritogenic properties in animal models; thirdly, its
co-localization with TNF receptors in RA synovium and the
pannus-cartilage junction; and fourthly, its pivotal role in
regulating the production of interleukin (IL)-1 in cultured
RA-derived synovial cells (a mixture of lymphoid cells,
macrophages, dendritic cells, B cells, endothelial cells,
and fibroblasts) [4,5].
Support for the role of TNFα in RA, and hence its promise
as a therapeutic target candidate, came from the observa-
tion that the clinical signs and tissue damage of collagen-
induced arthritis in mice were ameliorated by
administration of a monoclonal anti-TNFα antibody [6]. In
1992, 20 patients with active RA despite treatment with
disease-modifying antirheumatic drugs were the first to be
treated with an anti-TNFα agent, infliximab (Remicade®,
Centocor, Inc, Malvern, Pa). In this open-label clinical trial
by our group at the Kennedy Institute of Rheumatology
Division, the safety and marked anti-inflammatory effect of
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intravenously administered infliximab was associated with
a dramatic reduction in C-reactive protein (CRP) and ery-
throcyte sedimentation rate [7]. A multicenter, randomized,
placebo-controlled trial in Europe quickly followed and
confirmed the anti-inflammatory effect of a single intra-
venous infusion of infliximab [8]. However, most patients
relapsed within 3 to 8 weeks demonstrating the require-
ment for repeat therapy [9]. The duration of benefit before
relapse was related to the size of the drug dose (1 or
10 mg/kg).
The efficacy and optimal dose of infliximab, as well as an
enhanced therapeutic efficacy when coadministered with
methotrexate (MTX), was subsequently established in a
follow-up, randomized, controlled clinical trial [10,11]. The
consistency of a sustained therapeutic clinical response in
long-term treatment (2 years) with infliximab plus MTX
under double-blinded, placebo-controlled conditions has
now been demonstrated in the international, multicenter
Anti-Tumor necrosis factor Trial in Rheumatoid Arthritis
with Concomitant Therapy (ATTRACT) [12–14]. Patients
were randomized to receive either four dose schedules of
infliximab plus weekly doses of MTX (median dose
15 mg/wk) or MTX alone. Serial radiographs performed at
24, 54, and 102 weeks of this trial have revealed retarda-
tion or arrest (and even improvement in 39% to 54% of
patients) of both joint space narrowing (which equates
with cartilage loss) and bone erosion. These results are in
contrast to the progressive damage in the control group of
patients who were treated with MTX alone [12,14]. These
data are consistent with the hypothesis that TNFα plays a
key role in the perpetuation of inflammation and destruc-
tion of cartilage and bone in RA.
Infliximab
Infliximab, a chimeric (mouse Fv1, human IgG1) mono-
clonal antibody, specifically binds to both soluble and
membrane-bound TNFα with high affinity (Ka=1 0 10 M–1),
forming stable nondisassociating immune complexes [15].
The binding of infliximab to TNFα prevents the binding of
TNFα to its receptors and blocks the initiation of the intra-
cellular signaling that leads to gene transcription and sub-
sequent biologic activity. The binding of infliximab to
membrane-bound TNFα in vitro results in lysis of cell lines
via a complement- or antibody-dependent cell cytotoxicity
mechanism [16,17]. Whether this in vitro action has an in
vivo correlate has not been confirmed. The similarity of
clinical results observed for infliximab and etanercept,
another anti-TNF agent, suggests that cell lysis may not be
a necessary prerequisite, as etanercept does not exhibit
similar cell lytic properties in vitro.
Treatment of RA patients with infliximab has provided an
opportunity for clinical investigations that have illuminated
aspects of its cellular and molecular bases of action and
have provided insights into the pathogenesis of RA.
Pharmacokinetics and clinical response
Therapeutic response to infliximab correlates with the
pharmacokinetics of infliximab and basal expression of
TNFα in synovial tissue. Measurements of infliximab blood
levels and TNFα expression in joints suggest that TNFα
blockade at the site of production — mainly by cells of the
macrophage lineage in the joint — is the key to its mode of
action. There are close relationships between the dose of
infliximab administered, infliximab blood concentrations,
the durability of the clinical response, and eventual return
of all clinical features following its clearance from blood
[10,11]. Infliximab given repeatedly at a dose of 1 mg/kg
was associated with a rapid loss of therapeutic response
and accelerated clearance from the blood [10]. However,
this study also demonstrated the synergy of infliximab
when combined with MTX (Figure 1) [10], which is in part
explained by a lowered incidence of anti-infliximab anti-
bodies observed with combination therapy. These data
indicate that the antibody affects the effector mechanisms
and apparently does not terminate the more proximal
events that drive the disease process. As approximately
60% to 70% of patients show an initial response to inflix-
imab, it seems likely that, in a subset of the nonresponder
population (defined by the ACR response), TNFα is not
the key pivotal molecule regulating the cytokine network at
that point of the disease course. However, a clear clinical
and radiographic response has been noted in patients
who do not demonstrate a response as measured by ACR
20 criteria. This conclusion is supported by the documen-
tation of a correlation between a good clinical response to
infliximab only when, prior to treatment, there is a signifi-
cant level of expression of TNFα in synovial biopsies [18].
Infliximab regulates the cytokine network
It was noted in our first trial that, following the administra-
tion of infliximab, simultaneous reductions in CRP and IL-6
concentrations were observed in the blood [7]. This corre-
lation was clearly demonstrated in a subsequent study, as
was the rapid (within a few hours) reduction in serum IL-6
concentrations in infliximab-treated patients, but not in
patients receiving placebo (Figure 2) [19]. As CRP pro-
duction by hepatocytes is predominantly regulated by IL-6,
the data are consistent with the conclusion that downreg-
ulation of IL-6 production in RA joints was a consequence
of TNFα blockade. The dominant role of TNFα in the regu-
lation of IL-6 in RA demonstrated in vivo was entirely con-
sistent with the data obtained on the reduction of IL-6
production following the addition of anti-TNFα antibody to
RA synovial membrane cell cultures in vitro [20]. The
reduction of IL-1 synthesis in synovial tissue by an anti-
TNFα antibody in vitro was the pivotal observation that led
investigators to suspect the involvement of a cytokine
cascade in RA [21]; however, it has been more difficult to
verify these observations in vivo.  Quantification of
immunoreactive IL-1α and IL-1β by image analysis of syn-
ovial biopsies both before and 2 weeks after infliximabS24
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therapy revealed a reduction in, and linkage between,
TNFα and IL-1 synthesis [18]. Serologic analysis of
extremely low levels of IL-1 with different assays has
provided conflicting results, with significant reductions
observed in one laboratory and no consistent trend in
another laboratory [19,22].
Following infliximab therapy, a reduction in serum concen-
tration of IL-1ra (IL-1 receptor antagonist) and soluble TNF
receptors has also provided evidence that two major anti-
cytokines are regulated by TNFα (Figure 3) [19]. The
simultaneous reduction in pro-inflammatory and anti-
inflammatory molecules provides an interesting example of
the dominance of TNFα in the cytokine network and a pos-
sible explanation for why anti-TNFα therapy does not
restore a long-lasting remission but instead perpetuates
the cytokine imbalance, and hence there is relapse of
disease upon withdrawal of therapy.
Infliximab regulates cell recruitment
The marked reduction in the swelling and tenderness of
joints following infliximab treatment was shown in an early
study to be associated with a reduction in the cellularity of
the synovium of RA patients [23]. In a detailed immunohis-
tologic analysis of serial biopsies before and after inflix-
imab, it was observed that a reduction in CD3+ and
CD68+ cells was accompanied by a reduction in the adhe-
sion molecules vascular cell adhesion molecule-1, intercel-
lular adhesion molecule-1, and E-selectin [24]. Soluble
E-selectin and soluble intercellular adhesion molecule-1
concentrations in blood were similarly reduced by inflix-
imab, but not by placebo, and this reduction was closely
correlated with an increase in circulating lymphocytes [25].
In further studies, it was found that the expression of the
chemokines IL-8 and monocyte chemotactic protein-1 was
also reduced in synovial biopsies within two weeks follow-
ing infliximab therapy (Figure 4) [24,26,27]. These data
Figure 1
Efficacy, pharmacokinetics, and antibody incidence of infliximab. Efficacy of infliximab as (a) monotherapy (closed symbols) and (b) in combination
with methotrexate (open symbols) based on Paulus 20% criteria; infliximab 1 mg/kg (,), infliximab 3 mg/kg (,), infliximab 10 mg/kg (,),
and placebo plus methotrexate (). Arrows indicate the infusion times of infliximab and placebo. (c) Pharmacokinetics of infliximab alone (closed
symbols) or with methotrexate (open symbols); infliximab 1 mg/kg (,) infliximab 3 mg/kg (,), and infliximab 10 mg/kg (,). (d) Incidence of
anti-infliximab antibodies; infliximab alone (closed symbols) and infliximab plus methotrexate (open symbols). Panels a, b, and c, adapted with
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provided the evidence that anti-TNFα therapy regulates the
expression of adhesion molecules and chemokines on
rheumatoid vasculature. This led to the hypothesis that
reversing the migration of circulating leukocytes into
inflamed RA joints, and reversing their retention there,
might be an important mechanism of action.
Direct evidence of a reduction in leukocyte recruitment in
joints was obtained by gamma-camera imaging of
111indium-labelled autologous polymorphonuclear cells in
the hands and knees of RA patients before and after inflix-
imab therapy (Figure 5) [26]. Because inflammatory
disease is dependent on the influx of leukocytes, it is likely
that this reduction in leukocyte trafficking is an important
aspect of the mechanism of action of infliximab.
Infliximab regulates a major angiogenic factor and
angiogenesis
From the early stages of disease, rheumatoid synovial
inflammation is accompanied by a marked increase in
angiogenesis. The increase in blood vessel density pro-
vides a conduit for the increased trafficking of blood-borne
immune and inflammatory cells into joints. This increase in
trafficking leads to the formation of vascular pannus tissue
that invades and destroys cartilage and bone in the “bare
area” of the attachment of synovium to subchondral bone.
The cytokine vascular endothelial growth factor (VEGF) is
implicated in new blood vessel formation and is increased
in the joints and blood of RA patients [25,28,29]. Inflix-
imab therapy reduces circulating VEGF levels and the
density of neovasculature in the synovium [25,30]
(Figure 6). There is direct evidence of a reduction in the
number of blood vessels in infliximab-treated patients. A
reduction in angiogenesis may be relevant to our under-
standing of the anti-inflammatory and antidestructive prop-
erties of infliximab. In addition, although unproven, the
exudative leakage of plasma mediated by VEGF may also
be ameliorated by infliximab.
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Figure 2
Effect of infliximab on IL-6 concentrations. (a) Circulating IL-6 concentrations in patients treated with a single infusion of infliximab or placebo on
Day 0; infliximab 1 mg/kg (), infliximab 10 mg/kg (), and placebo (). *P < 0.05, **P < 0.01, ***P < 0.001 compared with placebo. (b) The
relationship between the reduction in circulating IL-6 by Day 3 and the reduction in C-reactive protein (CRP) over the same period (r = 0.59, 
P < 0.002). Adapted with permission from Charles et al. [19]. Copyright 1999. The American Association of Immunologists.
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Effect of infliximab on circulating IL-1ra in patients treated with a single
infusion of infliximab or placebo on Day 0. Infliximab 1 mg/kg (),
infliximab 10 mg/kg (), and placebo (). *P < 0.05, **P < 0.01, 
***P < 0.001 compared with placebo. Adapted with permission from
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Infliximab prevents cartilage catabolism and bone erosion
The most compelling evidence for the ability of anti-TNFα
therapy to prevent cartilage loss and bone erosions fol-
lowing the onset of disease was obtained by histologic
examination of joints in the collagen-induced arthritis
mouse model of RA [6]. In this model, preservation of
chondrocytes and cartilage matrix and the lack of pannus
invasion of bone were notable features in response to
treatment with infliximab. In RA patients in the ATTRACT
trial, protection of cartilage and bone was observed —
possibly with healing — as judged by comparison of base-
line and 54-week radiographs of hands and feet in
patients treated with infliximab [12,25]. This finding sup-
ports the conclusion that mechanisms of tissue destruc-
tion in RA are TNFα-dependent. Whether the
coadministration of MTX with infliximab plays a part in the
mechanism of action needs to be clarified. Because etan-
ercept as monotherapy significantly slowed progression
of bone erosions in early RA patients over one year com-
pared with MTX monotherapy, the bone-protective action
of anti-TNFα therapy is not in doubt [31]. A reduction in
matrix metalloproteinase-1 and matrix metalloproteinase-3
following infliximab treatment has been documented, and
although the cellular and molecular basis of anti-TNFα in
this regard is not yet understood, this implies that a
downregulation of matrix-degrading enzymes may be
involved [32].
In animal models, IL-1 appears to play a critical role in car-
tilage destruction; it has been proposed that IL-1 may be a
better therapeutic target in RA and that the joint protective
effect of anti-TNFα therapy involves regulation of IL-1 pro-
duction [33,34]. The activation and function of osteoclasts
appear to involve not only IL-1 and TNFα, but also the
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Figure 4
Histologic scores, expression of chemokines and adhesion molecules and lymphocyte counts before and after single infusion of infliximab. 
(a) and (b) Histologic scores of knee synovial biopsies before (shaded bar) and after (open bar) treatment by chemokine or adhesion molecule.
(c) Circulating lymphocytes; infliximab 10 mg/kg (), infliximab 1 mg/kg (), and placebo (). (d) Change in serum E-selectin concentrations;
infliximab 1mg/kg (), infliximab 10 mg/kg (), and placebo (). Panel a, data from Taylor PC et al. [26]; panel b, data from Tak PP et al. [24];














































receptor activator of NFκB ligand (RANKL), also known as
TNF-related activation-induced cytokine (TRANCE), and
the interaction of RANKL with RANK [35,36]. Further work
is necessary to delineate the relative importance of these
mechanisms.
Conclusion
Infliximab therapy for RA has illuminated the multiple path-
ways regulated by TNFα and its mechanism of action.
These studies have begun to unravel the complex cellular
and cytokine-dependent pathways that are involved and
have provided a new therapeutic benchmark. The lessons
we have learned will help to identify future research in
developing the next generation of antirheumatic drugs with
an improved efficacy and safety profile.
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